Gyawali Sudesh, Khan Gulam Muhammad, Lamichane Shreekrishna, Gautam Jaya, Ghimire Saurav, Adhikari Rashmi, Lamsal Reshma
Assistant Professor, Department of Pharmacology, Manipal College of Medical Sciences (MCOMS) , Deepheight, Pokhara, Nepal .
J Clin Diagn Res. 2013 Jun;7(6):1135-9. doi: 10.7860/JCDR/2013/5309.3058. Epub 2013 Jun 1.
Avipattikar churna, a poly-herbal formulation, is one of the popular ayurvedic formulations which is used for peptic ulcer diseases but the scientific documentation with regards to its effect for the indication is lacking.
This study was carried out to evaluate the anti-secretory and the anti-ulcerogenic activities of the churna and to compare its activity with that of ranitidine in a pyloric ligated model of rats.
Four groups of rats with 6 animals in each served as the ulcer controls, churna low dose (500 mg/kg), churna high dose (750mg/kg) and ranitidine (25mg/kg). The control group rats received only vehicle (2% (v/v) gum acacia), while the rats of the other groups received the respective dose of the churna or ranitidine which was suspended in the vehicle. The treatments were given twice a day, orally, for two days. After 1 hour of the last dose, pyloric ligations were performed and the rats were sacrificed for evaluation after four hours of the ligations. The gastric contents were collected and its volume, pH and acidity were measured. The numbers of ulcers and their lengths were measured which were used to calculate the gastric irritancy index and the curative ratio. The histological examinations of the gastric tissues were also performed.
The churna, in both doses, significantly decreased the volumes of the gastric contents, the ulcer score, the length of the ulcer, the gastric irritancy index and pH increased as compared to those in the control group. The effects of the churna were comparable to that of ranitidine. The histopathological evaluation of the gastric tissue also supported the results.
Avipattikar churna has anti-secretory and anti-ulcerogenic effects which are comparable to those of ranitidine in peptic ulcer diseases.
阿魏帕蒂卡尔 churn（一种多草药配方制剂）是治疗消化性溃疡疾病常用的阿育吠陀配方制剂之一，但缺乏关于其治疗该适应症效果的科学文献记载。
本研究旨在评估 churn 的抗分泌和抗溃疡活性，并在大鼠幽门结扎模型中比较其与雷尼替丁的活性。
将四组大鼠，每组 6 只，分别作为溃疡对照组、churn 低剂量组（500 毫克/千克）、churn 高剂量组（750 毫克/千克）和雷尼替丁组（25 毫克/千克）。对照组大鼠仅接受赋形剂（2%（v/v）阿拉伯树胶），而其他组大鼠接受分别悬浮于赋形剂中的相应剂量的 churn 或雷尼替丁。每天口服给药两次，持续两天。在最后一剂给药 1 小时后，进行幽门结扎，结扎 4 小时后处死大鼠进行评估。收集胃内容物并测量其体积、pH 值和酸度。测量溃疡数量及其长度，用于计算胃刺激性指数和治愈率。还对胃组织进行了组织学检查。
与对照组相比，两种剂量的 churn 均显著降低了胃内容物体积、溃疡评分、溃疡长度、胃刺激性指数，且 pH 值升高。churn 的效果与雷尼替丁相当。胃组织的组织病理学评估也支持了该结果。
在消化性溃疡疾病中，阿魏帕蒂卡尔 churn 具有与雷尼替丁相当的抗分泌和抗溃疡作用。
